Related references
Note: Only part of the references are listed.Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
Pingyu Chen et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2021)
Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China
Yin Liu et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China
Shu Chen et al.
BMJ GLOBAL HEALTH (2020)
Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection
Hua Zhou et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2020)
Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
Haoya Yun et al.
BMJ OPEN (2020)
Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease
Lisa I. Backus et al.
HEPATOLOGY (2019)
Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis
A. M. Buchanan-Hughes et al.
QUALITY OF LIFE RESEARCH (2019)
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
Qunying Han et al.
VIROLOGY JOURNAL (2019)
Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China
Ying Yang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update
Aysegul Erman et al.
BMJ OPEN (2019)
The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study
Jie Wu et al.
HEPATOLOGY (2019)
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Lai Wei et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV
Julia B. Balmaceda et al.
ANTIVIRAL THERAPY (2019)
Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b
Yuchen Liu et al.
CLINICAL DRUG INVESTIGATION (2018)
Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens
Maissa El-Raziky et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2018)
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China
Yun Lu et al.
PLOS ONE (2018)
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China
Pingyu Chen et al.
CLINICAL DRUG INVESTIGATION (2018)
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
Rubesh Raja et al.
IMMUNOLOGICAL REVIEWS (2018)
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study
Ya-Chao Tao et al.
VIROLOGY JOURNAL (2018)
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
Chengguang Hu et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
THE COST-EFFECTIVENESS ANALYSIS OF ELBASVIR/GRAZOPREVIR VERSUS PEGINTERFERON ALPHA-2A IN COMBINATION WITH RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1B INFECTION IN CHINA
P. Y. Chen et al.
VALUE IN HEALTH (2018)
Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study
Hui-ying Rao et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution
Yu Zhang et al.
VIROLOGY JOURNAL (2017)
SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
Yanhua Li et al.
VIROLOGY JOURNAL (2017)
Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China
Hai Chen et al.
PLOS ONE (2017)
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
Mei-Hsuan Lee et al.
SCIENTIFIC REPORTS (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis
Bryony Simmons et al.
CLINICAL INFECTIOUS DISEASES (2016)
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
Dong Ji et al.
HEPATOLOGY INTERNATIONAL (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights
Matthias Gotte et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data
Guo-Feng Chen et al.
PLOS ONE (2016)
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
Mehdi Najafzadeh et al.
ANNALS OF INTERNAL MEDICINE (2015)
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
Jagpreet Chhatwal et al.
ANNALS OF INTERNAL MEDICINE (2015)
Natural History of Hepatitis C
Shilpa Lingala et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2015)
Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6
Wei Ju et al.
VIROLOGY JOURNAL (2015)
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection
Huiying Rao et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Hepatitis C drugs not reaching poor
Ewen Callaway
NATURE (2014)
Hepatitis C can be cured globally, but at what cost?
Andrew Hill et al.
SCIENCE (2014)
Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma A Meta-analysis of Observational Studies
Rebecca L. Morgan et al.
ANNALS OF INTERNAL MEDICINE (2013)
NASPGHAN Practice Guidelines: Diagnosis and Management of Hepatitis C Infection in Infants, Children, and Adolescents
Cara L. Mack et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2012)
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
Mark Roberts et al.
MEDICAL DECISION MAKING (2012)
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus
Amit G. Singal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis
Christophe Moreno et al.
JOURNAL OF HEPATOLOGY (2010)
Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis
Bin Wu et al.
VALUE IN HEALTH (2010)
Assessment of Total Economic Burden of Chronic Hepatitis B (CHB)-Related Diseases in Beijing and Guangzhou, China
Min Hu et al.
VALUE IN HEALTH (2009)
Share Paper
